K
27F0
vs
D
DAX Index
Over the past 12 months, 27F0 has underperformed DAX Index, delivering a return of -95% compared to the DAX Index's +9% growth.
Stocks Performance
27F0 vs DAX Index
Performance Gap
27F0 vs DAX Index
Performance By Year
27F0 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
KALA BIO Inc
Glance View
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 34 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
